The Name “Hypermobile Ehlers–Danlos Syndrome” is confusing, incorrect and it is a Potential for Diagnostic Confusion

Pradeep Chopra, MD, MHCM

Assistant Professor (Clinical)

Brown Medical School

Ehlers–Danlos syndromes (EDS) is defined as heritable connective-tissue disorders characterized by a core triad: joint hypermobility, skin hyperextensibility, and tissue fragility, with substantial genetic and phenotypic heterogeneity across 13 recognized subtypes. [1] This core definition already implies a central tension in the label “Hypermobile EDS (hEDS)”: joint hypermobility is not unique to hEDS and appears as a major or minor criterion in many of the other EDS subtypes. [1]

A rigorous reading of the 2017 criteria supports a nuanced conclusion [1]:

·      The claim that “hEDS” is potentially misleading has a strong conceptual basis in the structure of the 2017 nosology itself, because hypermobility is framed as

(a) a cross-cutting hallmark of EDS generally, and

(b) a descriptor found in many other syndromes beyond EDS. [1]

·      Evidence that the name “hEDS” directly causes clinician diagnostic error exists, but is mostly indirect, appearing as

(i)             repeated expert emphasis that hypermobility is a descriptor rather than a diagnosis;

(ii)            Repeated emphasis on hypermobility as a descriptor has lead clinicians to ignore pain and other co-morbidities that cause dysfunction

(iii)          repeated warnings that hEDS diagnosis requires structured criteria and careful exclusion of other heritable and acquired disorders that also include hypermobility; and

(iv)           broader documentation of knowledge gaps and diagnostic delays around hypermobility-related disorders. [2]

·      The strongest “name-driven confusion” signal in the literature is terminology drift and aggregation (e.g., conflation of “EDS” with hEDS, or combining EDS with joint hypermobility syndrome in epidemiologic claims), which has been explicitly shown to be true by a well-researched paper [3]

On balance, a renaming effort that de-emphasizes “hypermobility” as the defining identity of this subtype (without erasing its clinical centrality) could plausibly improve clinician reasoning and education by reducing “hypermobility = hEDS” heuristics. The key argument of this report is that the nomenclature “hypermobile EDS” is misclassified. This report proposes several alternative names that explicitly foreground systemic connective-tissue disorder framing, and outlines a concrete pathway for consensus-building and implementation.

hEDS currently lacks a definitive molecular marker in standard clinical practice; any naming change must avoid worsening the already challenging diagnostic criteria for hEDS and must be implemented with synchronized educational and coding updates to prevent short-term disruption.

The 2017 International Classification recognizes 13 EDS subtypes and proposes major and minor clinical criteria for each, with “minimal criteria suggestive” for clinical suspicion. Importantly, except for hEDS, the definite diagnosis relies on molecular confirmation because of genetic heterogeneity, phenotypic variability, and overlap with other heritable connective tissue disorders (HCTDs). [1]

Key interpretive point for the naming debate: across these criteria, joint hypermobility (generalized, small-joint, or distal) appears in 11 of the other EDS sub-types: cEDS (major), clEDS (major), cvEDS (major), vEDS (minor), aEDS (major), kEDS (major), BCS (minor), spEDS (gene-specific minor), mEDS (major), and pEDS (minor). [1] This directly supports the premise that “hypermobile” is cross-cutting, not uniquely discriminative.

Epidemiology and phenotype overlap across EDS subtypes

Prevalence and ascertainment

hEDS is widely described as the most common EDS subtype in clinical practice, but its population prevalence is not rare but often missed. The diagnosed point prevalence is 194.2 per 100,00 (roughly 1 in 500) for EDS and joint hypermobility syndrome. This research indicates that the condition is 10 times more common that the previously cited 1 in 5000 [4]. This may be partly because:

(a) it lacks a definitive molecular test and

(b) diagnostic criteria and labels have changed over time.

(c) Most physicians who do manage hEDS have not accepted or have reluctantly accepted the 2017 Classification because it has never been ratified by follow up robust clinical trials to test the validity.

It must be recognized that most diseases do not have a definitive molecular test for identification. In most conditions, the diagnosis is based on a medical history and clinical examination with or without laboratory or imaging studies.

By contrast, several rarer subtypes have published frequency ranges and clearer molecular confirmation pathways. For example, the 2017 vascular EDS management review estimates vEDS frequency as approximately 1/50,000–1/200,000. [5] Sub types such as classical EDS around 1/20,000–1/40,000 and vascular EDS around 1/50,000–1/250,000, while emphasizing that many subtypes are very rare and true prevalence is difficult to establish. [6]

A Welsh health-record study (records up to 2017): reported about 194.2 per 100,00 (roughly 1 in 500) for EDS and joint hypermobility syndrome with a recorded diagnosis of “EDS” or “JHS” and concluded these conditions were not rare [6]. One of the reasons for why physicians miss the diagnosis of hEDS is because of its nomenclature ‘Hypermobile”. The name implies that hEDS is the only subtype with joint hypermobility and that the predominant diagnostic criteria is hypermobile joints without realizing that hEDS is primarily a connective tissue disorder with significant systemic involvement.

Phenotype overlap that matters for naming

In the 2017 criteria for hEDS specifically, the criteria are intentionally broadened beyond “just joints.” This criteria includes systemic manifestations of a generalized connective tissue disorder (for example mild skin hyperextensibility, hernias, pelvic organ prolapse, and cardiac features such as mitral valve prolapse and aortic root dilation). [1] The classification also notes that systemic issues (including gastrointestinal disorders, dysautonomia, anxiety, and depression) may be more disabling than joint symptoms and should be assessed, even when not part of the diagnostic criteria. [1]

This creates a naming mismatch: the criteria increasingly emphasize multisystem connective-tissue manifestations, yet the subtype label still foregrounds a single high-salience physical sign (“hypermobile”). [1]

Evidence that the label “hEDS” can contribute to diagnostic confusion

This section distinguishes between:
(a) evidence of diagnostic confusion and misinterpretation in hypermobility-related care, and
(b) evidence that the name “hEDS,” specifically, is a causal driver.

Confusion is structurally “built in” to hypermobility-based labeling

The 2017 framework on joint hypermobility emphasizes a foundational point: joint hypermobility is a descriptor rather than a diagnosis and is “often a feature of a larger syndromic diagnosis.” [2] This statement directly supports the claim that a disease name anchored on “hypermobility” risks overgeneralization, because it highlights a feature that is shared across multiple syndromic entities. [2]

The same framework notes that many patients previously labeled as “EDS-hypermobility type (EDS-HT)” and “joint hypermobility syndrome (JHS)” had overlapping phenotypes, inconsistent separation, and lack of laboratory confirmation; the updated nosology unified these under hEDS but also left many symptomatic individuals who do not meet stricter criteria needing classification (leading to the HSD construct). [2] This history is relevant because broad and shifting use of “hypermobility-type” labels (including hEDS) can normalize the idea that hypermobility itself “equals” a single disease entity. [2]

Documented knowledge gaps and lived diagnostic burden in hypermobility-type EDS

A qualitative interview study of individuals with hypermobility-type EDS/JHS (conducted prior to the 2017 nosology but explicitly discussed in light of the updated labels) highlights themes including limited understanding among healthcare professionals and recommends efforts to “increase awareness of hypermobility among healthcare professionals.” [7] While this does not isolate the “hEDS” name as the cause, it supports the broader clinical reality that hypermobility-related disorders are frequently misunderstood, which increases the likelihood that a high-salience phenotype-based label will be used imprecisely. [7]

Direct “name-driven” confusion signals in stakeholder critiques

The most explicit published signal of terminology and naming confusion relevant to hEDS arises in controversies about what “EDS” denotes in aggregation.

This matters for the hEDS naming claim because it demonstrates how terminology choices affect clinician and public interpretation. The critique is not “the word hypermobile is wrong,” but it is an explicit example that labeling and aggregation in this domain repeatedly produce confusion significant enough that patients with hEDS who do not demonstrate significant joint hypermobility are denied the correct diagnosis.

What the current evidence does and does not prove

The available sources strongly support the worldview that

(i)             hypermobility is a cross-cutting sign across EDS subtypes and other syndromes;

(ii)            hEDS diagnosis is clinically challenging and requires structured exclusion; and

(iii)          terminology drift produces misunderstanding. [1]

However, the published record captured here provides less direct evidence that the specific string “hypermobile EDS” is independently responsible for clinician misdiagnosis beyond these broader cognitive and nosologic pressures. This distinction is important for advocacy strategy: a renaming proposal will be stronger if it is paired with measurable educational and diagnostic outcomes (e.g., reduced inappropriate labeling of generalized hypermobility as hEDS; improved referral for genetic testing when vascular red flags exist). [1]

Principles for disease nomenclature in genetic and connective tissue disorders:

Descriptive versus mechanistic (gene-based) naming

The EDS subtype names in the 2017 nosology are largely phenotype-descriptive (classical, vascular, hypermobile, kyphoscoliotic, etc.). [1] In many monogenic conditions, disease naming increasingly emphasizes gene–disease validity and genotype–phenotype relationships, because such naming tends to increase precision and reduce ambiguity across overlapping phenotypes. The Clinical Genome Resource (ClinGen) [8] disease naming guidance notes that heterogeneous historical naming conventions have produced “disparate and not always informative” disease names, and frames monogenic diseases as entities defined by causal genotype–phenotype relationships and population-level phenotypic spectrum. [8]

Applied to hEDS, the tension is immediate: the gene for hEDS as unknown, making a gene-based name currently infeasible. [1] This places hEDS in a category where phenotype-based naming is necessary, but the phenotype chosen for the label should ideally be

(a) discriminative and

(b) aligned with the syndrome’s multisystem nature.

Minimizing confusion and error as a naming objective:

The World Health Organization [9] has issued best-practice guidance for naming diseases that explicitly aims to minimize unnecessary negative effects and confusion. [9] Although that WHO document was produced in an infectious-disease context, its core logic generalizes: names should reduce misconception risk and avoid terms likely to mislead non-experts. [9]

Within EDS care, from a nomenclature standpoint, the phenotypic overlap is high and mislabeling is consequential (especially when vascular and tissue-fragility risks are at stake). [1]

‍